Skip to main content
SLXN
NASDAQ Life Sciences

Silexion 向德国提交了胰腺癌药物的关键性 2/3 期临床试验申请，扩大了 EU 的试验范围

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$0.761
Mkt Cap
$2.975M
52W Low
$0.7
52W High
$22.36
Market data snapshot near publication time

summarizeSummary

Silexion Therapeutics 已经成功向德国的 BfArM 提交了其领先的 siRNA 产品候选物 SIL204 的 2/3 期临床试验申请，目标是 KRAS 驱动的局部进展性胰腺癌。这一提交是一个关键的监管里程碑，德国将成为 EU 计划的报告成员国，并扩大了公司在主要欧洲市场的临床开发。这一行动是在之前从 BfArM 获得积极的科学建议和最近从以色列卫生部获得同一试验批准之后进行的。对于一家最近发出“存在疑虑”的警告的微型生物科技公司来说，其领先临床计划的这一进展具有高度的重要性，降低了资产的风险，并可能有助于未来的融资工作。交易者现在将监测 BfArM 的批准和计划于 2026 年第二季度启动的 2/3 期试验。

在该公告发布时，SLXN的交易价格为$0.76，交易所为NASDAQ，所属行业为Life Sciences，市值约为$297.5万。 52周交易区间为$0.70至$22.36。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SLXN - Latest Insights

SLXN
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Silexion Adjourns Shareholder Meeting to Vote on Massive Dilution, Reverse Split, and Equity Plan
Sentiment: Negative
View Wiseek Article
SLXN
Apr 28, 2026, 8:58 AM EDT
Filing Type: 8-K
Importance Score:
8
Silexion Therapeutics Submits Phase 2/3 CTA for Pancreatic Cancer Drug in Germany
Sentiment: Positive
View Wiseek Article
SLXN
Apr 28, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Submits Pivotal Phase 2/3 CTA for Pancreatic Cancer Drug to Germany, Expanding EU Trial
Sentiment: Positive
View Wiseek Article
SLXN
Apr 09, 2026, 4:26 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Massive Share Increase, Reverse Split, and Expanded Equity Plan Amidst Going Concern
Sentiment: Negative
View Wiseek Article
SLXN
Mar 31, 2026, 11:17 AM EDT
Filing Type: PRE 14A
Importance Score:
9
Silexion Re-Proposes Massive Share Increase, Reverse Split After Prior Rejection Amidst Delisting Risk
Sentiment: Negative
View Wiseek Article
SLXN
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Silexion Therapeutics Board Removes Director Ilan Levin Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
SLXN
Mar 24, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Silexion Therapeutics Receives Approval for Phase 2/3 Pancreatic Cancer Trial
Sentiment: Positive
View Wiseek Article
SLXN
Mar 24, 2026, 8:37 AM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Therapeutics Gains Israeli Approval for Pivotal Phase 2/3 Pancreatic Cancer Trial
Sentiment: Positive
View Wiseek Article
SLXN
Mar 23, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
Shareholders Reject Critical Capital Raise and Equity Plan Proposals Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
SLXN
Mar 17, 2026, 5:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Silexion Therapeutics Reports $6M Cash, Advances Pancreatic Cancer Drug to Phase 2/3 Trial
Sentiment: Neutral
View Wiseek Article